cbdMD, Inc. (YCBD) — Institutional Holders, Q2 2026
27 institutional investment managers reported a YCBD position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $487.4K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
YCBD in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- VANGUARD CAPITAL MANAGEMENTAdded · +68,592 sh+$46.2K
- Chicago Partners Investment GroupAdded · +64,598 sh+$43.5K
- NORTHERNNew · +14,903 sh+$10.0K
- StoneX GroupNew · +12,732 sh+$8.6K
- Virtu FinancialNew · +10,491 sh+$7.1K
Biggest sellers
- UBS Group AGTrimmed · -143,067 sh-$96.3K
- XTX Topco LtdTrimmed · -29,306 sh-$19.7K
- JANE STREET GROUPTrimmed · -21,937 sh-$14.8K
- NORTHWESTERN MUTUAL WEALTH MANAGEMENTSold out · -150 sh-$101.00
- FMRSold out · -22 sh-$15.00
YCBD 13F holders ranked 1–27 of 27
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | CSS#1 · 137,621 sh | 137,621 | $92.6K | <0.01% | 0.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 119,645 sh | 119,645 | $80.5K | 0.00% | +134.4% |
| 3 | CHAPIN DAVIS#3 · 81,250 sh | 81,250 | $54.7K | — | 0.0% |
| 4 | ALESCO ADVISORS#4 · 68,513 sh | 68,513 | $46.1K | <0.01% | 0.0% |
| 5 | Chicago Partners Investment Group#5 · 78,098 sh | 78,098 | $45.0K | — | +478.5% |
| 6 | XTX Topco Ltd#6 · 62,743 sh | 62,743 | $42.2K | <0.01% | -31.8% |
| 7 | JANE STREET GROUP#7 · 54,401 sh | 54,401 | $36.6K | 0.00% | -28.7% |
| 8 | VANGUARD FIDUCIARY#8 · 47,157 sh | 47,157 | $31.7K | 0.00% | 0.0% |
| 9 | UBS Group AG#9 · 21,576 sh | 21,576 | $14.5K | 0.00% | -86.9% |
| 10 | COMMONWEALTH EQUITY SERVICES#10 · 16,255 sh | 16,255 | $10.9K | 0.00% | 0.0% |
| 11 | StoneX Group#11 · 12,732 sh | 12,732 | $10.3K | <0.01% | New |
| 12 | NORTHERN#12 · 14,903 sh | 14,903 | $10.0K | 0.00% | New |
| 13 | Virtu Financial#13 · 10,491 sh | 10,491 | $7.0K | <0.01% | New |
| 14 | HARBOUR INVESTMENTS#14 · 5,200 sh | 5,200 | $3.5K | 0.00% | 0.0% |
| 15 | MORGAN STANLEY#15 · 1,139 sh | 1,139 | $767.00 | 0.00% | 0.0% |
| 16 | BlackRock#16 · 1,080 sh | 1,080 | $727.00 | 0.00% | 0.0% |
| 17 | OSAIC#17 · 63 sh | 63 | $41.00 | 0.00% | 0.0% |
| 18 | HHM Wealth Advisors#18 · 8 sh | 8 | $6.00 | 0.00% | 0.0% |
| 19 | Axiom Investment Management#19 · 7 sh | 7 | $5.00 | 0.00% | New |
| 20 | Golden State Wealth Management#20 · 2 sh | 2 | $2.00 | 0.00% | -50.0% |
| 21 | Farther Finance Advisors#21 · 3 sh | 3 | $2.00 | — | 0.0% |
| 22 | SRS Capital Advisors#22 · 1 sh | 1 | $1.00 | 0.00% | New |
| 23 | Rockefeller Capital Management L.P.#23 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
| 24 | CITIGROUP#24 · 1 sh | 1 | $1.00 | 0.00% | New |
| 25 | ROTHSCHILD INVESTMENT#25 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
| 26 | GROUP ONE TRADING, L.P.#26 · 2 sh | 2 | $1.00 | 0.00% | 0.0% |
| 27 | Worth Venture Partners#27 · 184,796 sh | 184,796 | — | — | 0.0% |
Funds that sold out of YCBD in Q2 2026 (4)
Held YCBD at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT150 sh | 150 | $111.00 |
| FMR22 sh | 22 | $17.00 |
| MAI Capital Management5 sh | 5 | $4.00 |
| Advisory Services Network2 sh | 2 | $1.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.